{
    "clinical_study": {
        "@rank": "15166", 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of azithromycin administered once a week in the\n      prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised\n      HIV-infected patients with a CD4 count < 100 cells/mm3."
        }, 
        "brief_title": "A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients", 
        "condition": [
            "Mycobacterium Avium-Intracellulare Infection", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Mycobacterium Infections", 
                "Mycobacterium avium-intracellulare Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Anti-pneumocystis prophylactic therapy (dihydropteroate synthetase inhibitors with or\n             without dihydrofolate reductase inhibitors, pentamidine).\n\n        Allowed:\n\n          -  Concomitant anti-HIV therapy (AZT, ddI, ddC) or antifungal therapy (including\n             azoles).\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count < 100 cells/mm3.\n\n          -  No MAC positive blood cultures within 1 month prior to study entry.\n\n          -  No symptoms suggestive of disseminated MAC infection (including unexplained diarrhea,\n             fever, and night sweats) within 1 month of study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Positive PPD within 3 months prior to study entry (negative PPD defined as < 5 mm\n             induration).\n\n          -  Chest x-ray suggestive of any active disease, in particular tuberculosis.\n\n          -  Known hypersensitivity to macrolide antibiotics.\n\n          -  Any other acute clinical condition likely to interfere with completion of the\n             protocol.\n\n          -  Inability to care for self without considerable assistance and medical care.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other investigational new drugs (except for foscarnet or ddC) unless prior agreement\n             has been reached between the investigator and the Pfizer project physician.\n\n          -  Concomitant putative immunostimulants.\n\n        Patients with the following prior conditions are excluded:\n\n        History of MAC or Mycobacterium tuberculosis (MTb) infection.\n\n        Prior Medication:\n\n        Excluded within the past 4 weeks:\n\n          -  Any putative anti-MAC therapies including rifampin, rifabutin, clofazimine,\n             ethambutol, cycloserine, ethionamide, amikacin, and ciprofloxacin or other quinolones\n             thought to be active against MAC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002309", 
            "org_study_id": "058I", 
            "secondary_id": "066-155"
        }, 
        "intervention": {
            "intervention_name": "Azithromycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "keyword": [
            "Mycobacterium avium-intracellulare Infection", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Azithromycin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "921345000"
                    }, 
                    "name": "San Diego Naval Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Bragg", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "283075000"
                    }, 
                    "name": "Womack Army Med Ctr / Med Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lackland Air Force Base", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "782365300"
                    }, 
                    "name": "United States Air Force Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Azithromycin as Prophylaxis Against the Development of Mycobacterium Avium Complex Disease in HIV-Infected People", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Oldfield EC, Dickinson G, Chung R, Wallace MR, Craig DB, Fessel WJ, Joyce MP, Mckee KT, Melcher G, Wagner KF, Williams WJ, Zajdowicz M, Heifits L, Dunne MW, Berman J. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002309"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "San Diego Naval Hosp": "32.715 -117.157", 
        "United States Air Force Med Ctr": "29.384 -98.581", 
        "Womack Army Med Ctr / Med Clinic": "35.139 -78.999"
    }
}